Psoriasis patients starting or switching systemic therapy: safety and real-world outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The CorEvitas Psoriasis Registry collects real-world data from approximately 200 North American sites to monitor safety, including adverse events of special interest like malignancy, among adults with moderate to severe plaque psoriasis on systemic or biologic therapies. It features a parallel structure modeled after the Corrona RA Registry and is co-managed by Corrona, LLC and the National Psoriasis Foundation. Patients who recently started or switched systemic psoriasis treatment can enroll, with data collected as part of routine care under physician supervision. All treatments are standard-of-care and decisions remain with the treating physician. Study procedures involve observational data collection without a specified interventional protocol.

Why it matters

Who can join: the full rules

ELIGIBILITY CRITERIA∗ To be eligible for enrollment into the CorEvitas Psoriasis Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below.

Inclusion Criteria:

The patient must:

1. Have been diagnosed with psoriasis by a dermatologist.
2. Be at least 18 years of age or older.
3. Be willing and able to provide written consent for participation in the registry.
4. Be willing and able to provide Personally Identifiable Information (PII) that includes the following types of personal information at a minimum: 1) Full Name and 2) Date of Birth.
5. Meet one of the following criteria.

Have started on or switched to a systemic psoriasis treatment within the previous 12 months†▲:

Exclusion Criteria:

1\. Patient is participating in or planning to participate in a double-blind randomized of a psoriasis drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded.

Where it's running

• Waltham, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Psoriasis Registry Team
• Email: ppd_corepsoriasis@thermofisher.com
• Phone: 6178655932

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

• SHR-1139 injectable treatment for adults with plaque psoriasis

  This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangzhou · NCT07719530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.